Skip to main content
Journal ArticleOPEN ACCESS

COVID-19 in patient with sarcoidosis receiving long-term hydroxychloroquine treatment, France, 2020

Emerging Infectious Diseases (2020) 26(10) 2513-2515
DOI: 10.3201/eid2610.201816
6Citations
Citations of this article
65Readers
Mendeley users who have this article in their library.

Abstract

Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19, despite adequate plasma concentrations.

Cite

CITATION STYLE

APA

Bénézit, F., Le Bot, A., Jouneau, S., Lemaître, F., Pronier, C., Lentz, P. A., … Tattevin, P. (2020). COVID-19 in patient with sarcoidosis receiving long-term hydroxychloroquine treatment, France, 2020. Emerging Infectious Diseases, 26(10), 2513–2515. https://doi.org/10.3201/eid2610.201816

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free